Philippe Moreau

Research interests

Publications

• Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

  New England Journal of Medicine · 2023 · 10.1056/nejmoa2303379

• Teclistamab in Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2203478

• Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma

  New England Journal of Medicine · 2021 · https://doi.org/10.1056/nejmoa2024850

• Multiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†

  Annals of Oncology · 2021 · https://doi.org/10.1016/j.annonc.2020.11.014

• Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)

  Leukemia · 2020 · 10.1038/s41375-020-0876-z

• Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

  New England Journal of Medicine · 2019 · 10.1056/nejmoa1817249

• Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)31240-1

• Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

  The Lancet · 2019 · https://doi.org/10.1016/s0140-6736(19)32556-5

• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

  New England Journal of Medicine · 2017 · 10.1056/nejmoa1611750

• Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

  Annals of Oncology · 2017 · 10.1093/annonc/mdx096

• Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group

  Blood · 2016 · 10.1182/blood-2016-01-631200

• Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1607751

• International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

  The Lancet Oncology · 2016 · https://doi.org/10.1016/s1470-2045(16)30206-6

• Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma

  New England Journal of Medicine · 2016 · 10.1056/nejmoa1516282

• Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

  New England Journal of Medicine · 2015 · 10.1056/nejmoa1505654

• Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report

  Blood · 2015 · 10.1182/blood-2014-12-615187

• Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group

  Journal of Clinical Oncology · 2015 · https://doi.org/10.1200/jco.2015.61.2267

• Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study

  The Lancet Oncology · 2015 · 10.1016/s1470-2045(15)00464-7

• Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial

  The Lancet Oncology · 2014 · 10.1016/s1470-2045(14)70440-1

• Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

  Nature Communications · 2014 · 10.1038/ncomms3997

• Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1402551

• Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma

  New England Journal of Medicine · 2014 · 10.1056/nejmoa1411321

• Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial

  The Lancet Oncology · 2013 · 10.1016/s1470-2045(13)70380-2

• Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

  New England Journal of Medicine · 2012 · 10.1056/nejmoa1114138

• Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

  The Lancet Oncology · 2011 · 10.1016/s1470-2045(11)70081-x

• Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

  Leukemia · 2011 · 10.1038/leu.2011.196

• Genetic abnormalities and survival in multiple myeloma: the experience of the Intergroupe Francophone du Myelome

  Blood · 2007 · 10.1182/blood-2006-08-040410

• Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis

  American Journal of Hematology · 2005 · https://doi.org/10.1002/ajh.20381

Current projects

No projects listed.